459 related articles for article (PubMed ID: 22487221)
1. Atovaquone versus trimethoprim-sulfamethoxazole as Pneumocystis jirovecii pneumonia prophylaxis following renal transplantation.
Gabardi S; Millen P; Hurwitz S; Martin S; Roberts K; Chandraker A
Clin Transplant; 2012; 26(3):E184-90. PubMed ID: 22487221
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of once-weekly dapsone dosing for Pneumocystis jirovecii pneumonia prophylaxis post transplantation.
Evans RA; Clifford TM; Tang S; Au T; Fugit AM
Transpl Infect Dis; 2015 Dec; 17(6):816-21. PubMed ID: 26369753
[TBL] [Abstract][Full Text] [Related]
3. Tolerability of low-dose sulfamethoxazole/trimethoprim for Pneumocystis jirovecii pneumonia prophylaxis in kidney transplant recipients.
Zmarlicka M; Martin ST; Cardwell SM; Nailor MD
Prog Transplant; 2015 Sep; 25(3):210-6. PubMed ID: 26308779
[TBL] [Abstract][Full Text] [Related]
4. Switch to atovaquone and subsequent re-challenge with trimethoprim-sulfamethoxazole for Pneumocystis prophylaxis in a kidney transplant population.
McLaughlin MM; Galal A; Richardson CL; Sutton SH; Barr VO; Patel N; Mitchell P; Stosor V
Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28833985
[TBL] [Abstract][Full Text] [Related]
5. Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases.
Kitazawa T; Seo K; Yoshino Y; Asako K; Kikuchi H; Kono H; Ota Y
J Infect Chemother; 2019 May; 25(5):351-354. PubMed ID: 30711257
[TBL] [Abstract][Full Text] [Related]
6. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation.
Colby C; McAfee S; Sackstein R; Finkelstein D; Fishman J; Spitzer T
Bone Marrow Transplant; 1999 Oct; 24(8):897-902. PubMed ID: 10516703
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation.
Prasad GVR; Beckley J; Mathur M; Gunasekaran M; Nash MM; Rapi L; Huang M; Zaltzman JS
BMC Infect Dis; 2019 Apr; 19(1):311. PubMed ID: 30953458
[TBL] [Abstract][Full Text] [Related]
8. Pneumocystis jirovecii pneumonia in renal transplant recipients: a national center experience.
Borstnar S; Lindic J; Tomazic J; Kandus A; Pikelj A; Prah J; Skvarc M; Godnov U; Kovac D
Transplant Proc; 2013 May; 45(4):1614-7. PubMed ID: 23726632
[TBL] [Abstract][Full Text] [Related]
9. Comparison of atovaquone and azithromycin with trimethoprim-sulfamethoxazole for the prevention of serious bacterial infections in children with HIV infection.
Hughes WT; Dankner WM; Yogev R; Huang S; Paul ME; Flores MA; Kline MW; Wei LJ;
Clin Infect Dis; 2005 Jan; 40(1):136-45. PubMed ID: 15614703
[TBL] [Abstract][Full Text] [Related]
10. Combination of caspofungin and low-dose trimethoprim/sulfamethoxazole for the treatment of severe Pneumocystis jirovecii pneumonia in renal transplant recipients.
Tu GW; Ju MJ; Xu M; Rong RM; He YZ; Xue ZG; Zhu TY; Luo Z
Nephrology (Carlton); 2013 Nov; 18(11):736-42. PubMed ID: 24571744
[TBL] [Abstract][Full Text] [Related]
11. High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis.
Souza JP; Boeckh M; Gooley TA; Flowers ME; Crawford SW
Clin Infect Dis; 1999 Dec; 29(6):1467-71. PubMed ID: 10585797
[TBL] [Abstract][Full Text] [Related]
12. Risk of Pneumocystis jiroveci pneumonia in patients long after renal transplantation.
Struijk GH; Gijsen AF; Yong SL; Zwinderman AH; Geerlings SE; Lettinga KD; van Donselaar-van der Pant KA; ten Berge IJ; Bemelman FJ
Nephrol Dial Transplant; 2011 Oct; 26(10):3391-8. PubMed ID: 21385859
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology and risk factors associated with Pneumocystis jirovecii pneumonia in kidney transplant recipients after 6-month trimethoprim-sulfamethoxazole prophylaxis: A case-control study.
Park SY; Jung JH; Kwon H; Shin S; Kim YH; Chong YP; Lee SO; Choi SH; Kim YS; Woo JH; Kim SH; Han DJ
Transpl Infect Dis; 2020 Apr; 22(2):e13245. PubMed ID: 31943590
[TBL] [Abstract][Full Text] [Related]
14. A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim-sulfamethoxazole, effects on the microflora, and the cost-benefit of prophylaxis.
Fox BC; Sollinger HW; Belzer FO; Maki DG
Am J Med; 1990 Sep; 89(3):255-74. PubMed ID: 2118307
[TBL] [Abstract][Full Text] [Related]
15. Combination of Echinocandins and Trimethoprim/Sulfamethoxazole for the Treatment of Pneumocystis jiroveci Pneumonia After Heart Transplantation.
Lu YM; Lee YT; Chang HC; Yang HS; Chang CY; Huang CM; Wei J
Transplant Proc; 2017 Oct; 49(8):1893-1898. PubMed ID: 28923644
[TBL] [Abstract][Full Text] [Related]
16. Prophylaxis of Pneumocystis carinii pneumonia with atovaquone in children with leukemia.
Madden RM; Pui CH; Hughes WT; Flynn PM; Leung W
Cancer; 2007 Apr; 109(8):1654-8. PubMed ID: 17345613
[TBL] [Abstract][Full Text] [Related]
17. Atovaquone for Prophylaxis of Toxoplasmosis after Allogeneic Hematopoietic Stem Cell Transplantation.
Mendorf A; Klyuchnikov E; Langebrake C; Rohde H; Ayuk F; Regier M; Christopeit M; Zabelina T; Bacher A; Stübig T; Wolschke C; Bacher U; Kröger N
Acta Haematol; 2015; 134(3):146-54. PubMed ID: 25968483
[TBL] [Abstract][Full Text] [Related]
18. Anidulafungin as an alternative treatment for Pneumocystis jirovecii pneumonia in patients who cannot tolerate trimethoprim/sulfamethoxazole.
Chen PY; Yu CJ; Chien JY; Hsueh PR
Int J Antimicrob Agents; 2020 Jan; 55(1):105820. PubMed ID: 31622654
[TBL] [Abstract][Full Text] [Related]
19. [Pneumocystis pneumonia in a renal transplant recipient].
Özkoç S; İnceboz T; Sıfıl A; Tuncay S; Akisü Ç
Turkiye Parazitol Derg; 2010; 34(4):186-9. PubMed ID: 21391190
[TBL] [Abstract][Full Text] [Related]
20. Late-onset Pneumocystis jirovecii pneumonia in solid organ transplant recipients.
Perez-Ordoño L; Hoyo I; Sanclemente G; Ricart MJ; Cofan F; Perez-Villa F; de la Bellacasa JP; Moreno A; Cervera C
Transpl Infect Dis; 2014 Apr; 16(2):324-8. PubMed ID: 24456244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
